CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

21-444

Microbiology Review(s)
Product Quality Microbiology Data Sheet

A. 1. NDA: 21-444/N-000
2. REVIEW NUMBER: 1
3. REVIEW DATE: 20 February, 2002
4. TYPE OF SUPPLEMENT: n.a.
5. SUPPLEMENT PROVIDES FOR: n.a.
6. APPLICANT/SPONSOR:
   Name: Janssen Research Foundation
   1125 Trenton–Harbourton Road
   Titusville, NJ 08560-0200
   Representative: Claude McGowan, Ph.D.
   Telephone: 609-730-3025
7. MANUFACTURING SITE: Janssen Ortho LLC
   State Road 933 Km 0.1
   Mamey Ward
   Gurabo, PR 00778
8. DRUG PRODUCT NAME:
   Proprietary: RISPERDAL®
   Non-proprietary: Risperidone
   Drug Priority Classification: S
9. DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY: 0.5 mg., 1 mg., and 2 mg. tablets.
10. METHOD(S) OF STERILIZATION: n.a.
11. PHARMACOLOGICAL CATEGORY: Drug used to treat schizophrenia.

B. 1. DOCUMENT/LETTER DATE: 11/16/01
2. RECEIPT DATE: 11/16/01
3. CONSULT DATE: 01/16/02
4. DATE OF AMENDMENTS: n.a.
5. ASSIGNED FOR REVIEW: 01/17/02
6. SUPPORTING/RELATED DOCUMENTS: n.a.
C. **REMARKS:** Janssen uses normal manufacturing and control of tableting and packaging with respect to microbial attributes. Limits for finished product are NMT 1000 Total Aerobic Count, NMT 100 Total Molds and Yeast, and freedom from E. coli and Salmonella. The product is _____ and packaged in _____ blister packs which helps prevent post packaging microbial growth.
Executive Summary

I. Recommendations
   
   A. The microbial limits specification for this dosage form are appropriate. Recommend approval of the basis of microbial quality. Reduction or elimination of microbiological testing will require a prior approval supplement,

   B. Recommendation on Phase 4 Commitments and/or Agreements, if Approvable – n.a.

II. Summary of Microbiology Assessments
   
   A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology - The formulation is —— to form the fast tablet. The tablets are packaged in a —— blister packs. Stability data indicates that the tablets do not change in moisture content or microbial content during two years storage at 70% Relative Humidity (R.H.) Release specifications for the USP <66> Microbial Limits Test are:
      - Total Aerobic Microbial Count, NMT 1000 cfu/gram
      - Total Combined Molds and Yeast Count, NMT 100 cfu/gram
      - Escherichia coli, Absent in 1 gram
      - Salmonella spp., Absent in 1 gram

   B. Brief Description of Microbiology Deficiencies – n.a.

   C. Assessment of Risk Due to Microbiology Deficiencies- n.a.

III. Administrative
    
   A. Reviewer’s Signature

   B. Endorsement Block
      J. L. McVey/ 03/01/02
      P. H. Cooney/

   C. cc. Original NDA 21-444
      HFD-120/Division File
Redacted 2 pages of trade secret and/or confidential commercial information
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

James McVey
3/4/02 09:11:15 AM
MICROBIOLOGIST

Peter Cooney
3/4/02 02:36:09 PM
MICROBIOLOGIST